Edition:
United Kingdom

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

21.17USD
14 Jun 2019
Change (% chg)

$-0.22 (-1.03%)
Prev Close
$21.39
Open
$21.29
Day's High
$21.50
Day's Low
$21.07
Volume
66,301
Avg. Vol
98,458
52-wk High
$24.78
52-wk Low
$11.45

Latest Key Developments (Source: Significant Developments)

Apellis Pharmaceuticals Qtrly Loss Per Share $0.87
Wednesday, 8 May 2019 

May 8 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS REPORTS FIRST QUARTER 2019 BUSINESS UPDATE AND FINANCIAL RESULTS.APELLIS PHARMACEUTICALS INC - CASH POSITION OF $288.2 MILLION AT QUARTER-END.APELLIS PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.87.  Full Article

Apellis Pharmaceuticals Says Public Offering Of 6.00 Mln Common Shares Priced At $17.00Per Share
Thursday, 7 Mar 2019 

March 7 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 6.00 MILLION COMMON SHARES PRICED AT $17.00PER SHARE.  Full Article

Apellis Pharmaceuticals Announces Collaboration With SFJ Pharmaceuticals For APL-2 In Hematologic Indications
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS ANNOUNCES COLLABORATION WITH SFJ PHARMACEUTICALS FOR APL-2 IN HEMATOLOGIC INDICATIONS.APELLIS PHARMACEUTICALS INC - APELLIS TO RECEIVE UP TO $120 MILLION IN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS FROM DEAL.APELLIS PHARMACEUTICALS INC - APELLIS RETAINS EXCLUSIVE WORLDWIDE COMMERCIAL RIGHTS TO APL-2 IN ALL INDICATIONS.APELLIS PHARMACEUTICALS INC - DEAL HAS POTENTIAL FOR ADDITIONAL PAYMENTS SUBJECT TO MUTUAL AGREEMENT.APELLIS PHARMA - SFJ MAY ALSO PAY CO ADDITIONAL $50 MILLION IN FUNDING FOR PNH CLINICAL PROGRAM FOLLOWING A SPECIFIED, PRE-DEFINED CLINICAL MILESTONE..APELLIS PHARMACEUTICALS - HAS OPTION TO BUY-OUT OF ALL OR PART OF MILESTONE PAYMENTS AT ANY TIME FOLLOWING REGULATORY APPROVAL AT A DISCOUNTED RATE.  Full Article

Apellis Pharmaceuticals Reports Fourth Quarter Results
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.APELLIS PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.65.APELLIS PHARMACEUTICALS INC - PHASE 3 GEOGRAPHIC ATROPHY PROGRAM EXPECTED TO RESTART BY OR IN Q2 2019.APELLIS PHARMACEUTICALS - AS OF DEC 31, 2018, HAD $176.3 MILLION IN CASH AND CASH EQUIVALENTS, COMPARED TO $175.6 MILLION AS OF DEC 31, 2017.  Full Article

Apellis Pharmaceuticals QTRLY Loss Per Share $0.64
Tuesday, 13 Nov 2018 

Nov 13 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS REPORTS THIRD QUARTER 2018 BUSINESS UPDATE AND FINANCIAL RESULTS.CASH POSITION OF $220.6 MILLION AT QUARTER-END.QTRLY LOSS PER SHARE $0.64.COMMENCED PHASE 3 PROGRAM OF APL-2 IN GEOGRAPHIC ATROPHY.Q3 EARNINGS PER SHARE VIEW $-0.69 -- THOMSON REUTERS I/B/E/S.  Full Article

Apellis Pharmaceuticals Qtrly Loss Per Share $0.43
Monday, 30 Apr 2018 

April 30 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 BUSINESS UPDATE AND FINANCIAL RESULTS.APELLIS PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.43.APELLIS PHARMACEUTICALS - APL-2 IN GEOGRAPHIC ATROPHY AND PAROXYSMAL NOCTURNAL HEMOGLOBINURIA ON TRACK TO ADVANCE INTO PHASE 3 TRIALS IN 2H18.  Full Article

Apellis Pharmaceuticals Files For Offering Of 5 Million Shares Of Common Stock
Monday, 16 Apr 2018 

April 16 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS INC FILES FOR OFFERING OF 5,000,000 SHARES OF COMMON STOCK - SEC FILING.  Full Article

Apellis Pharmaceuticals Q4 Loss Per Share $0.61
Monday, 19 Mar 2018 

March 19 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.APELLIS PHARMACEUTICALS INC QTRLY LOSS PER SHARE $0.61.  Full Article

Apellis Finalizes Late Stage Trial Plans For Eye Disease Treatment
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Apellis Pharmaceuticals Inc ::APELLIS FINALIZES PHASE 3 CLINICAL TRIAL PLANS FOR GEOGRAPHIC ATROPHY TREATMENT WITH APL-2.APELLIS PHARMACEUTICALS INC - PHASE 3 PROGRAM EVALUATING APL-2 PLANNED TO BEGIN IN SECOND HALF OF 2018.APELLIS PHARMACEUTICALS - PHASE 3 PROGRAM TO CONSIST OF TWO IDENTICAL 600-PATIENT STUDIES TO ASSESS EFFICACY,SAFETY.APELLIS PHARMACEUTICALS INC - PHASE 3 TRIALS EVALUATING APL-2 WILL BE SUBSTANTIALLY SIMILAR IN DESIGN TO APELLIS' ONGOING PHASE 2 FILLY TRIAL.  Full Article

Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Apellis Pharmaceuticals Inc :Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc ‍​as of November 13 - SEC filing.  Full Article